Valeant Deal Would Aid Afexa’s Cold-FX Expansion Plans
This article was originally published in The Tan Sheet
Executive Summary
Valeant Pharmaceuticals International’s acquisition of Afexa Health Sciences likely will boost efforts to transition Afexa’s Cold-FX from a Canadian natural health product to a U.S. pharmaceutical.
You may also be interested in...
In Brief
Takeda makes Brazilian OTC play; Valeant supplements Canadian portfolio; NAD cools Add Lib libido claims; Triu Naturals hedges on ERSP recommendation; Dr. Reddy’s launches lansoprazole; more news In Brief.
Valeant Includes OTCs In Bid For Dramatic Growth By 2013
The Ontario-based firm has its sights set on becoming a top-15 pharma company with a $50 billion market capitalization by the end of 2013. Emerging markets and consumer health products, including the recent iNova and Fleming deals, play a big part in Valeant’s plans.
Valeant Includes OTCs In Bid For Dramatic Growth By 2013
The Ontario-based firm has its sights set on becoming a top-15 pharma company with a $50 billion market capitalization by the end of 2013. Emerging markets and consumer health products, including the recent iNova and Fleming deals, play a big part in Valeant’s plans.